Genetic Screens Reveal FEN1 and APEX2 as BRCA2 Synthetic Lethal Targets
Genetic Screens Reveal FEN1 and APEX2 as BRCA2 Synthetic Lethal Targets
复制标题
DOI:
10.1016/j.molcel.2018.12.008
复制
发表时间:
2019-03-07
期刊:
影响因子:
16
通讯作者:
Elledge, Stephen J.
中科院分区:
文献类型:
--
作者:
Mengwasser, Kristen E.;Adeyemi, Richard O.;Elledge, Stephen J.
BRCA1 or BRCA2 inactivation drives breast and ovarian cancer but also creates vulnerability to poly(ADP-ribose) polymerase (PARP) inhibitors. To search for additional targets whose inhibition is synthetically lethal in BRCA2-deficient backgrounds, we screened two pairs of BRCA2 isogenic cell lines with DNA-repair-focused small hairpin RNA (shRNA) and CRISPR (clustered regularly interspaced short palindromic repeats)-based libraries. We found that BRCA2-deficient cells are selectively dependent on multiple pathways including base excision repair, ATR signaling, and splicing. We identified APEX2 and FEN1 as synthetic lethal genes with both BRCA1 and BRCA2 loss of function. BRCA2-deficient cells require the apurinic endonuclease activity and the PCNA-binding domain of Ape2 (APEX2), but not Ape1 (APEX1). Furthermore, BRCA2-deficient cells require the 5' flap endonuclease but not the 5'-3' exonuclease activity of Fen1, and chemically inhibiting Fen1 selectively targets BRCA-deficient cells. Finally, we developed a microhomology-mediated end-joining (MMEJ) reporter and showed that Fen1 participates in MMEJ, underscoring the importance of MMEJ as a collateral repair pathway in the context of homologous recombination (HR) deficiency.